Free tool
FAERS Monitor: Abilify Asimtufii
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217006 or its brand name (Abilify Asimtufii, Aripiprazole). Reports on generic versions are filed under their own applications.
Reports
42,627
Serious
36,055
85% of reports
Hospitalization
16,757
Death reported
3,410
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,434
- off label use2,968
- product use in unapproved indication2,295
- drug interaction2,287
- weight increased2,186
- anxiety1,806
- condition aggravated1,714
- suicide attempt1,584
- fatigue1,553
- suicidal ideation1,456
- toxicity to various agents1,429
- nausea1,388
- somnolence1,372
- sedation1,329
- schizophrenia1,308
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 68 |
| 2005 | 111 |
| 2006 | 161 |
| 2007 | 217 |
| 2008 | 192 |
| 2009 | 256 |
| 2010 | 342 |
| 2011 | 354 |
| 2012 | 534 |
| 2013 | 428 |
| 2014 | 584 |
| 2015 | 1,211 |
| 2016 | 1,456 |
| 2017 | 2,955 |
| 2018 | 3,363 |
| 2019 | 3,484 |
| 2020 | 3,049 |
| 2021 | 3,704 |
| 2022 | 3,702 |
| 2023 | 4,183 |
| 2024 | 4,341 |
| 2025 | 4,314 |
| 2026 | 3,618 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,011,532 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| schizophreniaSignal | 1,308 | 59.4 | 56.1 | 67,006 |
| sedationSignal | 1,329 | 26.3 | 24.9 | 30,748 |
| suicide attemptSignal | 1,584 | 13.2 | 12.6 | 17,446 |
| suicidal ideationSignal | 1,456 | 8.0 | 7.6 | 8,749 |
| drug interactionSignal | 2,287 | 7.2 | 6.9 | 12,125 |
| weight increasedSignal | 2,186 | 4.9 | 4.7 | 6,692 |
| product use in unapproved indicationSignal | 2,295 | 4.6 | 4.4 | 6,484 |
| toxicity to various agentsSignal | 1,429 | 4.2 | 4.0 | 3,490 |
| somnolenceSignal | 1,372 | 3.4 | 3.2 | 2,301 |
| anxietySignal | 1,806 | 3.1 | 3.0 | 2,659 |
| condition aggravatedSignal | 1,714 | 2.8 | 2.7 | 1,987 |
| off label use | 2,968 | 1.7 | 1.6 | 838 |
| drug ineffective | 4,434 | 1.7 | 1.6 | 1,243 |
| fatigue | 1,553 | 1.0 | 0.9 | 0 |
| nausea | 1,388 | 0.9 | 0.8 | 30 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.